Ecofibre Past Earnings Performance
Past criteria checks 0/6
Ecofibre's earnings have been declining at an average annual rate of -70.8%, while the Pharmaceuticals industry saw earnings growing at 47.3% annually. Revenues have been declining at an average rate of 4.9% per year.
Key information
-70.8%
Earnings growth rate
-68.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 31.2% |
| Revenue growth rate | -4.9% |
| Return on equity | -223.4% |
| Net Margin | -230.1% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Ecofibre Limited (ASX:EOF) Might Not Be As Mispriced As It Looks After Plunging 39%
Apr 24
Is Ecofibre (ASX:EOF) Using Too Much Debt?
Apr 13Lacklustre Performance Is Driving Ecofibre Limited's (ASX:EOF) 28% Price Drop
Feb 20Ecofibre Limited's (ASX:EOF) Shares Bounce 30% But Its Business Still Trails The Industry
Jan 03Does Ecofibre (ASX:EOF) Have A Healthy Balance Sheet?
Sep 29Is Ecofibre (ASX:EOF) A Risky Investment?
Jun 22We Think Ecofibre (ASX:EOF) Has A Fair Chunk Of Debt
Oct 29Would Ecofibre (ASX:EOF) Be Better Off With Less Debt?
Mar 05One Forecaster Is Now More Bearish On Ecofibre Limited (ASX:EOF) Than They Used To Be
Jun 04Ecofibre (ASX:EOF) Has Debt But No Earnings; Should You Worry?
Mar 31Would Shareholders Who Purchased Ecofibre's (ASX:EOF) Stock Year Be Happy With The Share price Today?
Mar 05We Wouldn't Rely On Ecofibre's (ASX:EOF) Statutory Earnings As A Guide
Feb 07What You Need To Know About Ecofibre Limited's (ASX:EOF) Investor Composition
Jan 04
Should You Be Excited About Ecofibre Limited's (ASX:EOF) 21% Return On Equity?
Dec 14Ecofibre's (ASX:EOF) Stock Price Has Reduced 49% In The Past Year
Nov 26Revenue & Expenses BreakdownBeta
How Ecofibre makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 30 | -68 | 16 | 3 |
| 30 Sep 23 | 31 | -54 | 18 | 4 |
| 30 Jun 23 | 33 | -40 | 21 | 5 |
| 31 Mar 23 | 31 | -32 | 21 | 6 |
| 31 Dec 22 | 30 | -24 | 22 | 7 |
| 30 Sep 22 | 30 | -20 | 21 | 7 |
| 30 Jun 22 | 30 | -15 | 21 | 6 |
| 31 Mar 22 | 30 | -11 | 19 | 6 |
| 31 Dec 21 | 30 | -8 | 18 | 6 |
| 30 Sep 21 | 29 | -8 | 18 | 5 |
| 30 Jun 21 | 29 | -7 | 19 | 4 |
| 31 Mar 21 | 33 | -3 | 20 | 3 |
| 31 Dec 20 | 36 | 1 | 21 | 2 |
| 30 Sep 20 | 44 | 7 | 21 | 2 |
| 30 Jun 20 | 51 | 13 | 21 | 2 |
| 31 Mar 20 | 51 | 13 | 22 | 2 |
| 31 Dec 19 | 51 | 13 | 22 | 2 |
| 30 Sep 19 | 43 | 10 | 21 | 1 |
| 30 Jun 19 | 36 | 6 | 19 | 0 |
| 31 Mar 19 | 27 | 0 | 18 | 0 |
| 31 Dec 18 | 18 | -7 | 16 | 0 |
| 30 Sep 18 | 12 | -8 | 13 | 0 |
| 30 Jun 18 | 6 | -9 | 11 | 0 |
| 30 Jun 17 | 1 | -9 | 5 | 0 |
Quality Earnings: EOF is currently unprofitable.
Growing Profit Margin: EOF is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EOF is unprofitable, and losses have increased over the past 5 years at a rate of 70.8% per year.
Accelerating Growth: Unable to compare EOF's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EOF is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16%).
Return on Equity
High ROE: EOF has a negative Return on Equity (-223.37%), as it is currently unprofitable.